Finally, in an inconclusive phase II follow-up [33▪] to a positive proof of concept for the mGlu2/3 receptor agonist LY2140023 monohydrate, none of the tested arms separated from placebo, including the active olanzapine arm. This trial had a large placebo effect (14 points on total PANSS). As olanzapine did not separate from placebo, it is reasonable to present this trial as an inconclusive trial, rather than a negative trial. Follow-up phase III trials are ongoing.
